EMA Authorised: Tecentriq (atezolizumab) — Roche Registration GmbH

View source ↗

Summary

The European Medicines Agency authorized Tecentriq (atezolizumab) by Roche Registration GmbH for multiple cancer indications, including non-small-cell lung canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Non-small Cell Lung Cancer
• Small Cell Lung Cancer
• Transitional Cell Carcinoma
• Urothelial Carcinoma

Drugs mentioned

• Tecentriq (atezolizumab)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Transitional Cell;Carcinoma, Non-Small-Cell Lung;Urologic Neoplasms;Breast Neoplasms;Small Cell Lung Carcinoma. MAH: Roche Registration GmbH. Decision date: 26/03/2026